Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3291 - Real world cfDNA collection in EGFR-mutant NSCLC

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Targeted Therapy

Tumour Site

Presenters

Nicolas Marcoux

Citation

Annals of Oncology (2018) 29 (suppl_8): viii479-viii482. 10.1093/annonc/mdy294

Authors

N. Marcoux1, L.V. Sequist1, A. Hata1, M. Banwait1, I. Dagogo-Jack1, R. Nagy2, R.B. Lanman2, A. Muzikansky3, S.R. Digumarthy4, Z. Piotrowska1

Author affiliations

  • 1 Hematology/oncology, Massachusetts General Hospital, 02114 - Boston/US
  • 2 Medical Affairs, Guardant Health, 94063 - Redwood City/US
  • 3 Biostatistics, Massachusetts General Hospital, 02114 - Boston/US
  • 4 Thoracic Radiology, Massachusetts General Hospital, 02114 - Boston/US
More

Resources

Abstract 3291

Background

Plasma cell-free DNA (cfDNA) assays are increasingly used in clinic. Despite their rapid adoption, best practices for use and interpretation need better definition. We assessed key clinically-relevant questions using a prospectively collected cohort of EGFR-mutant pts.

Methods

Starting in 2015, serial cfDNA testing via Guardant360 NGS was obtained from MGH pts with advanced EGFR-mutant NSCLC across multiple lines of therapy in an IRB-approved project. Medical records were analyzed retrospectively, tissue was genotyped by institutional NGS (SNaPshot), scans were assessed by RECIST. Correlations were tested by Wilcoxon Rank-Sum.

Results

372 plasma samples were collected from 89 pts, covering 150 therapy regimens including 26 drugs (targeted, immune, cytotoxic). To assess genotype correlation, we examined matched cfDNA and tissue biopsies at clinical progression for 60 regimens (51 pts). cfDNA-tissue concordance was 73% for founder EGFR mutations (n = 60), 72% for T790M (n = 60) and 89% for MET amp (n = 53). Excluding 15 samples without detectable founder mutation (presumed “non-shedders”), concordance for T790M=89% and MET=90%. To assess if relative change in cfDNA allelic fraction (AF) correlates with radiographic response, we examined 21 regimens (19 pts) with cfDNA samples at baseline and ≤ 30 days, and 3 aspects of the Guardant360 report. 12/21 regimens yielded PR by scans. Decrease in cfDNA AF in the 1st month of therapy correlated with ultimate PR whether assessing the change in AF of founder EGFR (p = 0.03), largest AF regardless of gene (p = 0.02) or sum of all detected AFs (p = 0.02).

Conclusions

CommercialcfDNA assays are readily available, facilitate serial AF monitoring and provide clinically-relevant data at acquired resistance. Among EGFR pts, we found real world cfDNA-tissue correlation of founder mutations and T790M was high and resistance mutation (T790M, MET) results in cfDNA may be most reliable when founder EGFR mutations are detected. Importantly, MET amp had high cfDNA-tissue concordance, which was unexpected. Early AF decrease (within 1st month of therapy) significantly correlates with radiographic response regardless of which aspect of the Guardant360 report is considered. Further investigation is needed to inform optimal use and interpretation of cfDNA assays.

Clinical trial identification

Legal entity responsible for the study

MGH Cancer Center.

Funding

Guardant Healthcare, Lungevity.

Editorial Acknowledgement

Disclosure

N. Marcoux: Honoraria: Bristol-Myers Squibb. L.V. Sequist: Consulting fees: AstraZeneca, Pfizer, Genentech; Institutional research funding: AstraZeneca, Novartis, Merck, Boehringer Ingelheim, Genentech, Merrimack, Incyte. A. Hata: Research/grant support: Novartis, Amgen, Relay Therapeutics. I. Dagogo-Jack: Honoraria: Foundation Medicine; Consulting: Boehringer Ingelheim. R. Nagy, R.B. Lanman: Stock ownership and employee: Guardant Health, Inc. Z. Piotrowska: Consulting/honoraria: AstraZeneca, Ariad/Takeda, GuardantHealth, Novartis, AbbVie; Research support (to institution): Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.